Editorial: Interventional therapy of hepatocellular carcinoma

Abstract

Globally, liver cancer is the most frequent fatal malignancy. In the United States, it ranks fifth (Sung et al., 2021). Patients are often diagnosed with liver cancer in advanced stages, contributing to its poor prognosis. Of all liver cancer cases, >90% are hepatocellular carcinomas (HCCs) (Sung et al., 2021). Currently, the incidence and mortality are increasing worldwide. Liver cancer is an extraordinarily heterogeneous malignant disease among the tumors that have so far been identified. HCC arises most frequently in the setting of chronic liver inflammation and fibrosis and takes a variety of course in individual patients to process to tumor. Because of the complex anatomy of the liver and association with underlying liver disease, management of these patients has been a challenge, considering both tumor and patient factors.